Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
4.635
+0.075 (+1.64%)
Streaming Delayed Price
Updated: 11:59 AM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
January 30, 2022
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 28, 2022
January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
GAINERS: Field Trip Health (NASDAQ:
Via
Benzinga
Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri
January 24, 2022
Psychedelics Legalization Gains Momentum Around The Country: Bills Introduced In Utah, Virginia, Kansas And Missouri A wave of psychede...
Via
Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
January 23, 2022
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
GAINERS: GH Research (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
January 19, 2022
GAINERS: Revive Therapeutics (OTC:
Via
Benzinga
Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows
January 19, 2022
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:
Via
Benzinga
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
January 19, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of...
Via
FinancialNewsMedia
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
GAINERS: Cybin (AMEX:
Via
Benzinga
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
January 10, 2022
Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA In a groundbreaking decision, the Canadian gov...
Via
Benzinga
A Recap of How Psychedelics Fared in 2021
January 07, 2022
Via
Investor Brand Network
Psilocybin Does Not Produce Adverse Effects On Cognition Or Emotional Function, New Study Finds
January 04, 2022
A new study is shedding light on the safety profile of psilocybin, the active ingredient in so-called “magic mushrooms.&rdqu...
Via
Benzinga
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
January 02, 2022
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the...
Via
Talk Markets
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
December 30, 2021
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv...
Via
Benzinga
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
The Year In Review For Psychedelic Drug Stocks: 2021
December 21, 2021
2021 was two different
Via
Talk Markets
Why Jim Cramer Likes MGM Growth Properties
December 21, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enterprise Products Partners L.P. (NYSE:
Via
Benzinga
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
December 17, 2021
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:
Via
Benzinga
Compass Pathways (NASDAQ: CMPS) Announces Promising Data from Psilocybin Therapy Trial
December 13, 2021
Via
Investor Brand Network
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
December 13, 2021
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:
Via
Benzinga
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
December 14, 2021
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept...
Via
FinancialNewsMedia
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
December 12, 2021
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways
December 07, 2021
Via
Investor Brand Network
Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways
December 06, 2021
Coda Signature Taps Teddy C. Scott As Board Member Producer of cannabis-infused edibles and wellness products Coda Signature
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.